Phaseline

Targets › SELL

SELL (L-selectin): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 2; Other; next expected readout Oct 2029.

Calcium-dependent lectin that mediates cell adhesion by binding to glycoproteins on neighboring cells. Mediates the adherence of lymphocytes to endothelial cells of high endothelial venules in peripheral lymph nodes. (UniProt, P14151)

Open in Phaseline: the race on SELL, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hong Kong Children's HospitalCD62L depleted donor lymphocyte infusion
CD62L-depleted donor lymphocytes for T cell reconstitution and graft-versus-tumor effect
SELLPhase 2Hematopoietic Organs; Disorder; Hematopoietic Cell TransplantationOct 2029

Conditions

Hematopoietic Organs; Disorder (1) Hematopoietic Cell Transplantation (1)

Modalities

protein or peptide (1)

Companies

Hong Kong Children's Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.